Hunan Jiudian Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

Born in 2001 and stepping onto the Shenzhen Stock Exchange in October 2017 under ticker 300705, Hunan Jiudian Pharmaceutical has grown into a vertically integrated drugmaker with a headcount of over 2,200 (including an R&D team of more than 400), two manufacturing plants and over 60 GMP production lines producing APIs, excipients, herbal extracts and finished medicines while offering CMO/CDMO services; by July 2025 the company carried a market value of about 8.09 billion yuan, institutional investors held roughly 12.03% and insiders ~47.21%, it repurchased 0.3 million shares for ~4.99 million yuan, and its core topical analgesics (Loxoprofen and Ketoprofen gel patches) deliver nearly 1.6 billion yuan in annual sales-backed by accolades such as national high-tech enterprise status, a 76th-place ranking among Hunan's Top 100 manufacturers in 2024, a joint venture with 100 million yuan registered capital (50% stake), FDA on-site inspections with zero 483 observations, and plans to roll out indomethacin and ibuprofen gel patches in 2025, all while expanding into e-commerce and sustaining social-responsibility initiatives

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ): Intro

• Founded in 2001, Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) began as a Chinese pharmaceutical developer and manufacturer focused on R&D, production and sales of medicines domestically and internationally.
• In October 2017 the company completed an IPO and was listed on the Shenzhen Stock Exchange under stock code 300705, a milestone that accelerated capital access and expansion.
• By 2024 the company ranked 76th on the Hunan Top 100 Manufacturing Enterprises list, reflecting its regional manufacturing scale and influence.

• Publicly traded company: shares listed under 300705.SZ; ownership comprised of institutional investors, retail investors and company insiders as typical for listed Chinese pharmas.
• Key subsidiaries include:
  • Hunan Jiudian Hongyang Pharmaceutical Co., Ltd. - focuses on active pharmaceutical ingredients (APIs) and excipients.
  • Hunan Pudao Pharmaceutical Technology Co., Ltd. - provides one-stop CXO (contract development & manufacturing organization) services.

• Mission: develop safe, effective and accessible medicines while expanding manufacturing and R&D capabilities to serve domestic and international markets.
• Strategic priorities:
  • Strengthen R&D pipeline via an in-house team of >400 professionals (as of 2025).
  • Vertical integration of APIs and excipients to improve cost control and supply security.
  • Expand CXO services to leverage manufacturing capacity and capture contract revenue.

• Broad therapeutic coverage including:
  • Analgesic drugs
  • Cardiovascular medications
  • Anti-infectives
  • Digestive and urinary system treatments
  • Respiratory and anti-allergy products
  • Nutritional supplements

• Revenue streams:
  • Finished-dosage pharmaceutical product sales (domestic hospitals, pharmacies and export markets).
  • API and excipient sales via Hunan Jiudian Hongyang Pharmaceutical.
  • Contract development and manufacturing (CXO) services through Hunan Pudao Pharmaceutical Technology - fee-for-service and long-term manufacturing contracts.
  • Licensing and technology transfer income from proprietary formulations and processes.
• Value drivers:
  • R&D capacity (400+ R&D staff) enabling new product introductions and lifecycle management of key products.
  • Integrated supply chain (APIs → formulations → CXO) that reduces production cost and improves margin control.
  • Public listing (300705.SZ) provides capital for capacity expansion, R&D investment and potential M&A to broaden the portfolio.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ): History

• Established core manufacturing and R&D bases in Hunan, expanding GMP-compliant facilities in multiple phases.
• Expanded product mix from TCM decoctions and proprietary Chinese medicines to include over-the-counter drugs, health supplements and cosmetics.
• Launched online retail operations and formed JV partnerships to accelerate innovation and market access.

• Strategic JVs: Hunan Jiu Dian Shannuo Innovative Pharmaceutical Technology Co., Ltd. - registered capital 100 million yuan; Jiudian holds 50%.
• E-commerce expansion: Hunan Ginseng Manman E-commerce Co., Ltd. - retail focus on cosmetics and health products to capture online consumer demand.

• Mission & Vision: Focus on integrating traditional Chinese medicine heritage with modern pharmaceutical R&D, expanding consumer access via retail and e-commerce. See the company's stated direction: Mission Statement, Vision, & Core Values (2026) of Hunan Jiudian Pharmaceutical Co., Ltd.
• Business model - revenue streams:
  • Manufacturing & sales of proprietary TCM and modern pharmaceutical products (largest revenue contributor).
  • Wholesale distribution to hospitals, pharmacies and TCM clinics.
  • Direct-to-consumer retail via brick-and-mortar and Hunan Ginseng Manman e-commerce platform (growing share of sales).
  • Contract manufacturing and technology JV revenues (R&D collaboration and licensing through partners like the 50%-owned Shannuo JV).
• Operational mechanics:
  • R&D pipeline leverages TCM formulations validated through modern quality controls; new product launches target OTC and health supplement segments with higher margins.
  • Cost management via in-house production, scale of regional manufacturing and selective outsourcing for non-core SKUs.
  • Share repurchases (e.g., Mar 2025) used to support share price and return capital, indicating management confidence in valuation.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ): Ownership Structure

• Mission and values: 'Health is our mission, and life depends on it' - integrating Chinese and Western medicines with a focus on patient outcomes and safety.
• R&D and innovation: operates a National Enterprise Technology Center and a Postdoctoral Research Station; recognized as a national high‑tech enterprise by the Ministry of Science and Technology.
• Quality & sustainability recognitions: awarded titles such as 'National Green Factory' and 'Hunan Provincial Intelligent Manufacturing Benchmark Enterprise.'
• Social responsibility: active in anti‑epidemic donations and targeted poverty alleviation initiatives.

• Strategic/controlling shareholders (founders/management and affiliated entities)
• Institutional investors (domestic funds, insurance, QFII/foreign institutions)
• Retail/public float (A-share holders on Shenzhen exchange)

• Product portfolio: prescription TCM formulations, integrated Chinese‑Western therapeutic products, and OTC/health products sold through hospitals, distributors and retail channels.
• Revenue drivers: clinical sales to hospital channels, expansion of OTC and community pharmacy distribution, licensing or co‑development agreements for innovative formulations.
• Cost structure: manufacturing and quality control, raw materials (herbal and chemical), R&D investment, regulatory compliance and sales/marketing.
• Value creation: proprietary formulations, clinical evidence and integrated TCM/Western positioning that command premium pricing in niche therapeutic areas.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ): Mission and Values

• Quality-first production with GMP-compliant facilities and full traceability across the supply chain.
• Customer partnership through CMO/CDMO offerings to accelerate drug development and commercial supply.
• Operational excellence via intelligent manufacturing and digital transformation to improve yield and lower unit costs.
• Regulatory rigor-demonstrated by passing U.S. FDA on-site inspections with zero Form 483 observations.

• Manufacturing footprint: two main production plants supporting API, excipient, herbal extract and finished-product manufacturing.
• Production capacity: more than 60 modern production lines operating under GMP standards to guarantee consistent batch quality and traceability.
• Quality and compliance: systems and procedures enabling successful international inspections, including U.S. FDA on-site inspections with zero 483 findings.
• Intelligent manufacturing: digital systems for process monitoring, MES/ERP integration, and automation that raise throughput and reduce variability.
• Service model: CMO/CDMO offerings for global pharmaceutical customers covering development, scale-up and commercial manufacturing.

• API sales: commercial supply of small-molecule APIs to domestic and international formulators.
• Excipients and herbal extracts: sales to finished-dosage manufacturers and traditional medicine companies.
• Finished products: branded and contract-manufactured dosage forms sold through distribution partners.
• CMO/CDMO services: fee-based development and manufacturing contracts (R&D development fees, technology transfer, scale-up and commercial supply contracts).
• Value-add services: analytical testing, stability studies and regulatory support for customers entering export markets.

• Full-life-cycle traceability: batch-level tracking from raw material receipt through finished-product release and distribution.
• GMP compliance across >60 production lines: consistent processes and documentation to reduce defect rates and regulatory risk.
• FDA readiness: demonstrated capability to meet stringent overseas regulatory expectations (zero 483 observations in U.S. FDA on-site inspections).
• Digital transformation: data-driven process controls, paperless quality systems and production optimization to lower cost per unit and improve OEE.

• Vertical integration reduces reliance on third-party suppliers for key intermediates and excipients, improving margin resilience.
• Extensive GMP manufacturing capacity allows capacity leasing through CMO contracts during periodical demand fluctuations.
• Proven regulatory compliance reduces commercialization risk for international customers seeking reliable contract manufacturing partners.
• Digital and intelligent manufacturing investments improve throughput, lower per-unit manufacturing cost and support scalable contract manufacturing.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ): How It Works

• Proprietary pharmaceutical product sales - analgesics (notably Loxoprofen and Ketoprofen topical patches), cardiovascular agents and anti-infectives.
• CMO/CDMO services - contract manufacturing and development for domestic and global clients, including formulation development, pilot/scale-up and commercial production.
• E-commerce and retail - cosmetics, health supplements and OTC retail via subsidiary Hunan Ginseng Manman E-commerce Co., Ltd.
• Joint ventures and partnerships - technology and product development through entities such as Hunan Jiu Dian Shannuo Innovative Pharmaceutical Technology Co., Ltd.
• Brand & quality certifications - titles like "National Green Factory" and "Hunan Provincial Intelligent Manufacturing Benchmark Enterprise" that enhance procurement and B2B contracting opportunities.

• R&D & product lifecycle - internal formulation teams and JV partners develop topical and systemic drugs; successful formulations move into pilot scale and commercial production.
• Manufacturing & quality - in‑house GMP facilities and "National Green Factory" recognition enable large‑scale, compliant production for own brands and CMO clients.
• Sales & distribution - dual channel strategy: institutional (hospitals, pharmacies) for prescription/OTC pharmaceuticals and direct‑to‑consumer e‑commerce/retail for OTC and cosmetic lines.
• Client services (CMO/CDMO) - fixed‑fee and milestone contracts for development plus recurring revenue from long‑term manufacturing agreements.
• Monetization of scale - high-volume products (e.g., analgesic patches) deliver margin leverage; awards and certifications improve tender success rates and premium contracting.

• Core product performance: Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch achieved combined annual sales near 1.6 billion yuan, representing the backbone of product revenue.
• Margin mix: proprietary product sales drive gross revenue; CMO/CDMO contributes higher gross margin per unit but depends on utilization and contract mix.
• Growth levers: expanding CMO client base, online retail scale‑up via Hunan Ginseng Manman E‑commerce, and commercialization of JV innovations.

Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ): How It Makes Money

• Core product sales: Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch - combined annual sales nearly ¥1.6 billion.
• Pipeline expansion: planned launches of indomethacin and ibuprofen gel patches in 2025 to broaden market reach and cross-sell into existing distribution channels.
• Manufacturing & supply: revenues from contract manufacturing and bulk API/finished-dose sales to domestic distributors and hospitals.
• Innovation & licensing: income from technology transfer, licensing of formulations, and collaboration on clinical or regulatory dossiers.

• Market position: strong regional manufacturing presence (Top 100 Hunan) and national innovation recognition improve pricing power and distributor trust.
• Future outlook: new 2025 gel-patch SKUs plus continued investment in intelligent, green manufacturing are positioned to sustain mid-to-high single-digit to double-digit revenue growth, assuming market uptake of new patches and stable margins on existing core products.